Tag: Samsung
FiercePharmaAsia—Biocon, Mylan’s Lantus copy; Samsung rides COVID demand; Adlai Nortye’s C...
Mylan and Biocon will launch Semglee, their biosimilar of Sanofi's Lantus, at a discount. Samsung Biologics' $2 billion "Super Plant" expansion is the result...
Samsung Biologics plots $2B ‘super plant’ as COVID-19 sends sales through...
The COVID-19 pandemic has caused shockwaves across the pharmaceutical industry with some drugmakers booking major losses in recent months. But the crisis hasn't been a...
